Tuesday, August 4, 2020
News
NEWS HOME
»
PRESS RELEASES

LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer
  SocialTwist Tell-a-Friend  
   


Date: 16-07-2020 10:14AM
Source: LintonPharm Co. Ltd.
Category: General, Govt. & Public Policy, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Guangzhou, China

Business Wire India

LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell engaging bispecific antibodies for cancer immunotherapy, today announced the China National Medical Products Administration (NMPA) authorized the company to proceed with a Phase III trial (clinicaltrials.gov: NCT04222114) for catumaxomab in patients with peritoneal carcinomatosis, a form of advanced gastric cancer that has spread to the tissue that lines the abdominal cavity.

The two-stage, multi-center, open-label, randomized, controlled registrational clinical trial will evaluate the safety and efficacy of an intraperitoneal infusion of the bi-specific antibody catumaxomab into the abdominal cavity in patients with peritoneal carcinomatosis. LintonPharm also recently received Clinical Trial Application (CTA) authorization for the same indication from the Taiwan Ministry of Health and Welfare (MOHW) and the Korea Ministry of Food and Drug Safety (MFDS).

“We are excited to re-initiate clinical development of catumaxomab which we believe may have benefit in a broad range of cancers,” said Robert Li, co-founder and CEO of LintonPharm. “Our initial development strategy is based on a robust foundation of clinical data that support the therapeutic potential of catumaxomab in advanced gastric cancer.”

Catumaxomab was the first T-cell engaging bispecific antibody approved by the European Medicines Agency (EMA) in 2009 for the treatment of malignant ascites, a fluid buildup in the peritoneal cavity that indicates the presence of malignant cells. It was later voluntarily withdrawn from the market for commercial reasons.

“Gastric cancer is the sixth most common cancer globally. Approximately 70 percent of patients are located in China and the majority of these patients are diagnosed with late stage disease. Given this high unmet need, we are hopeful that catumaxomab will offer a new treatment option to gastric patients,” said Dr. Horst Lindhofer, co-founder and Chief Scientific Officer of LintonPharm.

About Advanced Gastric Cancer with Peritoneal Carcinomatosis

Gastric cancer is the sixth most common cancer globally with an estimated incidence of 1,033,701 cases and 782,685 deaths in 2018.1About 70 percent of gastric cancer patients are located in China, with 679,100 new cases and 489,000 deaths2 in 2015. More than 70 percent of Chinese patients are diagnosed with late stage (stage III or IV) gastric cancer. Peritoneal carcinomatosis (PC) is one of the primary causes of death in late stage gastric cancer. Approximately 20 percent of patients are diagnosed with PC before or during surgery, and more than 50 percent of patients are diagnosed with PC after cancer reduction surgery. The prognosis for gastric cancer with PC is extremely poor, with an expected survival of less than one year3. Current therapies for gastric cancer include trastuzumab for Her2 positive patients and systemic chemotherapies (1st line and 2nd line). There are limited options for patients who fail frontline therapies, especially for those who developed PC.

About Catumaxomab

Catumaxomab is a trifunctional bispecific antibody which originated from Lindis Biotech’s Triomab platform. The antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T-cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab kills tumor cells by engaging T-cell and accessory cell mediated cytotoxicity and has potential to induce long-term vaccinal effects against tumor cells due to the unique FcγR binding and activation profile.

Catumaxomab was first approved by the EMA in 2009 for the treatment of malignant ascites (MA). MA is manifested as the abnormal accumulation of fluid in the peritoneal cavity, which develops from the proliferation of peritoneal carcinomatosis tumor cells in the cavity. There are various cancers that generate MA, for example ovarian, gastric, pancreatic and colorectal cancers. Patients with MA are usually diagnosed in the advanced stages of disease and their quality of life is greatly impaired. Currently, these patients face an extremely poor prognosis with a median overall survival of one to six months.

About LintonPharm

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. The company’s lead development program is with catumaxomab, a clinically validated bispecific antibody which was the first approved T-cell engager, and its associated Triomab technology platform. LintonPharm, in collaboration with Lindis Biotech, is also developing a next generation bispecific antibody platform known as Fleximab which aims to provide better CMC developability and less immunogenicity. The LintonPharm pipeline includes several treatments in development for blood cancer and solid tumors that use the Triomab and Fleximab platforms. For more information, please visit www.lintonpharm.com.

References

  1. Freddie Bray et. al., Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018; 68: 394-424.
  2. Wanqing Chen et. al., Cancer Statistics in China, 2015. CA Cancer J. Clin 2016; 66: 115-132
  3. China anti-cancer Association, Gastric Cancer, China Experts Consensus on Gastric Cancer with Peritoneal Carcinomatosis Prevention and Treatment;Chin J Gastrointest Surg, May 2017, Vol. 20, No. 5.



CONTACTS :

Media:
Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306

More Press Releases

Moody’s Analytics Repeats IFRS 9 Wins at Risk Technology Awards

First Eagle to Open Its First German Office in More Than 80 Years; New Hire Louanges Will Direct International Wholesale Business From Munich

Hengli Petrochemical Announces Start-up of its 5th PTA Line Utilising INVISTA’s P8 PTA Technology

Dole Unveils Integrated Strategy Against Banana Disease

Spykke Innovations Partners with tracesafe, to Launch Unique COVID Safety Wristbands in India

Freedom for Our Girls: Breaking Menstrual Barriers

Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

Craft Silicon and PayU Announce Strategic Association to Advance Digital Loan Repayment Solutions for Lending Institutions

With World’s 1st AI and ML Powered Annual-Recurring-Subscription-Model, Frinza Is All Set to Disrupt the Global Gifting Industry

Crossbeats Brings You Work from Home’s Best Bud in Its Beast of a New True Wireless Earphones

Preferred Equity Offering of Lead Real Estate via a Digital Securities Issuance, Brought to Market by GRIP, Securitize and Rialto

Andersen Global Continues West African Expansion with Addition of Tax and Legal Firm in Benin

New One-Stop Resource Center Gives Developers a Robust Array of Tools to Easily Manage, Monitor and Integrate Limelight Services

India Angel Fund invests in Mental Wellness Startup IPHM Services, round led by Monaliesa Sarkar, Jyoti Tiwari, Koel Dutta, Sabana Khatoon, Dr. Vikaas Grover and Rahul Narvekar

CoinEx $50M Ecosystem Development Fund Points First Investment as OneSwap

Wipro Selected as Strategic Partner by Metro Bank to Drive IT Transformation

Velodyne Lidar Sensors Power Emesent’s Hovermap to Fly Beyond the Visual Line of Sight

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trialin adults with and without diabetes

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

NWFI Says Everyone is Looking at India as an Alternative to China and Allowing Exports Will Boost the Domestic Industry

UL Issues First Safety Mark for Hyperbaric Chambers in India

Abbott and 1mg Bring Continuous Glucose Monitoring Solutions Closer to Indian Homes

Face Mask Killing Covid-19, Tested by US-Based ISO Certified Laboratory, Developed and Launched by an Indian Start-up

Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

Philips Introduces Revolutionary Haircare High-Tech Devices and DIY Female Grooming Products

Taobao Introduces Maker Rating System to Champion Young Entrepreneurs, Originality

Sustainable Mica Policy and Vision Prepared by Responsible Mica Initiative with Jharkhand Government and Civil Society Support

MOGAS Wins Multimillion Dollar Bid to Supply Valves for Southeast Asian Refinery

Bank of Baroda’s Credit Card Arm Readies for Digital Transformation with Implementation of Fiserv Technology

Aspect Announces General Availability of Aspect Unified IP 7.4 SP1, the Premier Enterprise Contact Center Solution for High Volume Customer Outreach

Recipe for Growth: Balancing Health, Indulgence and Taste Key to Drive Biscuit and Cookie Growth in India

Automation Industry Leader, Armstrong Along With Indian Rocket Scientists Launched UWe Safe for Contactless 3D Sanitization

WorldRemit Wishing All Those Celebrating a Blessed Eid al Adha

DNSC Introduces the “Typhoon” C20590 MX, the World’s Lowest Cost 100 ppm Full-Color All-In-One MICR Inkjet System

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
'Conspirators behind Mujib killing, Hasi...
Lord Krishna to celebrate his 1st virtua...
Naidu sets 48-hr deadline for Jagan to w...
Odisha to promote cage culture fisheries...
Indian Army organises free veterinary ca...
Kerala revises norms for containment zon...
More...    
 
 Top Stories
Yediyurappa doing well, clinically ... 
Assam situation limps towards norma... 
Aayush Sharma pens a birthday note ... 
BSE's Q1 consolidated net profit at... 
Jiten Lalwani: This year has been o... 
Manipur CM innaugurates 300-bedded ... 
'Conspirators behind Mujib killing,... 
Ayushmann Khurrana champions women'...